In this study, we evaluated the performance of a point-of-care device, the CoaguChek XS Plus system, in the determination of prothrombin time and international normalized ratio (INR) based on ISO17593: 2007 criteria in Taiwanese patients. The underlying clinical and genetic factors were also investigated.
, Ming-Ta Michael Lee 4, 5 , Ming-Shien Wen 1, 6 Original Article
At a Glance Commentary
Scientific background of the subject CoaguChek XS plus system was released in October 2005 , what served as a fast and convenient device for INR monitoring. Patients receiving warfarin needs frequent INR monitor to avoid drug adverse reaction which may cause death. In this study, CoaguChek XS plus system was validated compared to laboratory CA-1500. Although CoaguChek XS system had been validated worldwide, Taiwan patients had not been assessed in clinical practice. This is the first CoaguChek XS performance study in Taiwan. The potential genetic factors and clinical factors that may interfere test are assessed.
What this study adds to the field
This study find that CoaguChek XS plus system reach about 90% clinical agreement compared to laboratory CA-1500 and elevated AST and ALT level have effect on CoaguChek XS system analysis. W arfarin, a widely prescribed oral anticoagulant, prevents thromboembolism in patients with deep vein thrombosis, atrial fibrillation, or prosthetic heart valve replacements. However, warfarin has a narrow therapeutic index, making it difficult for physicians to maintain the dose in a therapeutic range. To prevent warfarin-associated adverse reactions, it is advised that for patients receiving warfarin, the international normalized ratio (INR) is maintained within the range of 2.0-3.0 for atrial fibrillation and other thromboembolic disorders and within the range of 2.5-3.5 for mechanical heart valve patients. [1, 2] Patients with an INR exceeding 4.0 showed an increased risk of hemorrhaging, and patients were more likely to suffer from embolism if their INR value was lower than the therapeutic range. Most warfarin adverse reactions occur when treatment is initiated. Therefore, the INR must be monitored frequently after initiation of warfarin treatment. However, for outpatients receiving warfarin in Taiwan, frequent INR monitoring during the first 2 weeks is difficult. There are two reasons for this. First, outpatients undergo the INR test only when prescribed to do so by a physician; and second, frequent withdrawal of blood within a short time period adds to patients' discomfort levels. A non-invasive, quick INR test is essential to improve patient compliance with frequent INR monitoring.
The CoaguChek XS Plus system, a portable coagulation monitoring system, provides fast and effective point-of-care monitoring, with a measurement range of 0.8-8.0 INR. [3] Although the performance of the CoaguChek XS Plus system has been evaluated worldwide, the device has not been validated in Taiwan. To improve patient compliance, the CoaguChek XS Plus system is aimed at patients receiving warfarin in Taiwan. In this study, we evaluated the CoaguChek XS Plus system against the Sysmex CA-1500 system, using CA-1500-Thromborel S reagent, based on the ISO 17593:2007 standard criteria. [4] The standard stipulates the requirements for in vitro monitoring systems for oral anticoagulant therapy for both self-testing medical devices and clinical laboratory settings. Additionally, we evaluated the clinical and genetic factors that might cause a bias of ≥0.5 INR between the two methods.
Since CoaguChek XS system was released in October 2005, the performance of the device was evaluated. [3, 5, 6] As a portable device, the practice in self-management was studied. [7] [8] [9] And the convenience of its small sample need, the practice in children were accessed. [10, 11] Nowadays, the device was studied in different medical conditions, such as patients with ventricular assist devices or patients receiving telavancin. [11, 12] Although CoaguChek XS system had been validated worldwide, Taiwan patients had not been assessed in clinical practice. This is the first CoaguChek XS performance study in Taiwan. Moreover, the interference of clinical and genetic factors were discussed beyond other studies. The CoaguChek XS Plus system (Roche Diagnostics, Mannheim, Germany) consisted of the CoaguChek XS monitor and CoaguChek XS PT test strips. The device used a human recombinant thromboplastin with an International Sensitivity Index (ISI) value of 1.0 to activate the coagulation cascade in blood. The production of thrombin cleaves a peptide substrate on the test strip to generate an electrochemical signal. In this study, the system was calibrated according to the manufacturer's manual, the information of which was stored in a lot-specific microchip code included in every vial of the test strips. The results were presented as the PT in INR, %Quick, or seconds. Only the INR values were used for analysis.
METHODS

Study
Laboratory procedure
For the laboratory tests, venous blood samples were drawn by standard procedures into 3.2% sodium citrate tubes, serum-separating tubes, and dipotassium ethylenediaminetetraacetic acid (K2-EDTA) tubes (4.08 mM, final concentration). For the PT test, the centrifuged plasma was analyzed with the Sysmex CA-1500 (Sysmex Corporation, Kobe, Japan). The thromboplastin reagent used for the laboratory test was Thromborel S (Siemens Healthcare Diagnostics, Marburg, Germany), with an ISI of 0.95. Thromborel S reagent is lyophilized human placental thromboplastin. For the aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin, and creatinine tests, the centrifuged sera were analyzed with a Hitachi 7600
Biomed J Vol. 37 No. 6 November -December 2014 analyzer (Hitachi Inc., Tokyo, Japan). A complete blood count (CBC) test was done with Sysmex XE-5000 (Sysmex Corporation, Kobe, Japan). The genotyping method for CY-P2C9 (rs1057910, CYP2C9*3) and VKORC1 (rs9923231, VKORC1-1639 G > A) has been described previously. [13] Performance validation
Precision of the CoaguChek XS Plus system
The precision of the CoaguChek XS Plus system was evaluated using the Roche CoaguChek XS PT control with an INR value of approximately 1.8. Within-run precision was tested eight times in one run, and between-day precision was tested for 8 days. Finally, the mean INR, standard deviation (SD), and coefficient of variation (CV) were calculated. 
Accuracy of the CoaguChek XS Plus system
Clinical agreement
Clinical agreement was defined based on whether a bias existed between the results of the two methods for various warfarin dosages. Based on the standard therapeutic range of 2.0-3.0 for atrial fibrillation and 2.5-3.5 for patients with mechanical heart valves, we categorized the INR values as <2.0, between 2.0 and 3.5, and >3.5 to fit most of the clinical therapeutic range. The percentage of INR results reported by the CoaguChek XS Plus system and the laboratory CA-1500 method that fell within the same dosage categories was calculated.
Interferences of clinical and genetic factors
We found that several patients showed a high discrepancy in results between the CoaguChek XS Plus system and the laboratory CA-1500 method, with an INR bias ≥0.5. Depending on the method used, a different clinical decision for warfarin dosage may have been made by a physician, which may have caused an adverse outcome. Clinical and genetic factors were examined to determine whether any of these factors were able to cause differences in the INR (≥0.5 INR) between the CoaguChek XS Plus and laboratory CA-1500 methods. Clinical factors analyzed included the patient's demography (age, gender), biochemical data (AST, ALT, creatinine, albumin and hematocrit levels), and genetic data of CYP2C9 (rs1057910, CYP2C9*3) and VKORC1 (rs9923231, VKORC1-1639 G > A). We used Fisher's exact test to examine the significance of the results.
RESULTS
Of the 50 patients enrolled for this study, 62% were males and 38% were females. Fifty percent of the group exhibited atrial fibrillation, 32% showed deep vein thrombosis, and 18% showed other indications. The median age was 68 years. The 93 INR values collected ranged from 1.2 to 7.7 when measured with the CoaguChek XS Plus system, and from 1.2 to 6.5 when measured with the laboratory CA-1500 method. The mean INR and SD for each subgroup are shown in Table 1 . 
Clinical agreement
The clinical agreement was evaluated by determining whether the INR values of the two methods warranted the same medical prescription. In particular, the clinical agreement was evaluated with respect to whether or not the INR values fell within the same categories. Table 2 shows that 84 (90.3%) samples were categorized in the same subgroup. Three (3.2%) of the values obtained by CoaguChek XS Plus were falsely higher than those obtained by the CA-1500 method, and six (6.4%) were falsely lower.
Interference of clinical and genetic factors
We investigated whether clinical and genetic factors caused the discrepancies in the INR values that resulted in the two outliers on the bias plot. Patients with an INR bias ≥ − 0.5 in the entire detection range were also investigated. Ten samples from eight patients were selected.
Fisher's exact test indicated a significant difference in the liver function if AST was >34 u/L (3/8, 37.5% vs. 3/42, 7.1%, p = 0.044) and ALT was >36 u/L (3/8, 37.5% vs. 3/42, 7.1%, p = 0.044). Patients with hypoalbuminemia (3/8, 37.5% vs. 13/42, 31%, p = 0.699), elevated creatinine (3/8, 37.5% vs. 
Performance validation
Precision of the CoaguChek XS Plus system
The precision of CoaguChek XS was assessed by within-run and between-run CV%. The results showed a mean of 2.10, an SD of 0.08, and a CV of 3.60% for within-run precision and a mean of 2.18, an SD of 0.07, and a CV of 3.24% for between-run precision.
Accuracy of the CoaguChek XS Plus system based on the three ISO criteria Figure 1 shows the results of linear regression analysis. For each method, 93 INR values were collected. The correlation between the two methods showed a coefficient of correlation of 0.96, a slope of 1.05, and an intercept of −−0.14. Table 1 the SD was larger when compared with the other groups. Related studies have demonstrated that when the INR values exceeded the therapeutic range, the bias increased, especially when the INR values were above 4.5. [14, 15] The higher SD when the INR was above 4.5 related to both the World Health Organization (WHO) guidelines, which exclude samples with an INR outside the range of 1.5-4.5 for the ISI assignment. [16] Also, ISO 17593:2007 excludes samples with an INR beyond 6.0. Although the standard deviation was high when the INR value was above 4.5, the paired t-test indicated that the two methods were the same (p > 0.05) in the entire range and in each subgroup.
From the eight selected patients, 10 sets of INR values were ≥ ≥ − 0.5, those being (CA-1500/CoaguChek XS Plus): (2.5/2.0), (3.5/3.0), (5.5/7.7), (2.0/2.5), (6.2/7.1), (2.3/1.8), (2.5/3.0), (4.3/4.8), (1.4/2.0), and (3.1/3.9). Four of these sets of INR values, (1.4/2.0), (5.5/7.7), (6.2/7.1), and (3.1/3.9), as well as the two outliers in the bias plot showed exceptionally high variation. This variation might have resulted from clinical and genetic interferences. Although Plesch et al. found no significant variation between the CoaguChek XS and venous blood, [6] our study showed that patients who had an INR bias ≥ ≥ − 0.5 had elevated AST and ALT levels that both reached the significant impact level.
Previous studies have experienced interference because of technical problems and antiphospholipid antibody. Lisman et al. indicated that the insufficient performance of INR measurements in patients with end-stage liver disease was because the calibration reagent of the international standard index reagent did not come from liver disease patients, but came from normal pooled plasma. [17] Although the patients in this study did not have severe liver disease, our findings of abnormal AST and ALT levels suggest that plasma protein, such as albumin, or other globulins produced by the hepatobiliary system, may interfere with the CoaguChek XS Plus system. Is CoaguChek XS Plus system is still reliable in patients with abnormal liver function tests? The INR data sets of the three patients with abnormal liver function were (CA-1500/CoaguChek XS Plus): (2.5/2.0), (3.5/3.0, (5.5/7.7), (2.0/2.5), (3.1/3.9), and (2.2/2.4). Although the INR bias is ≥ ≥ − 0.5, the data sets will be classified into the same subgroups of clinical agreement range and also lead to the same dosage. Abnormal liver function is related to higher INR bias, but does not have an influence on dosage at this stage. So, CoaguChek XS Plus system is still reliable in the patients. However, limited by the sample size, these findings require further investigation.
Clinical agreement was used to decide on patients' dosages. In total, nine cases were classified into subgroups. The INR data sets of these nine cases were (1.4/2.0), (1.9/2.2), (2.0/1.9), (2.0/1.9), (2.0/1.8), (2.1/1.9), (2.3/1.8), (3.1/3.9), and (3.9/3.5) from the CA-1500 and CoaguChek XS Plus 
DISCUSSION
To our knowledge, this study is the first to evaluate the performance of the CoaguChek XS Plus system in Taiwan that considers the effects of clinical and genetic factors. We evaluated the performance of the CoaguChek XS Plus system using the three requirements of the ISO 17593:2007 standard. In the linear regression analysis, the coefficient of correlation (r) of 0.96 and a slope that fell within the range 0.95-1.05 fulfilled the ISO requirements. However, the intercept at − 0.14 was slightly outside the range of ± 0.1 INR. The intercept outside the allowable range may have been because our sample size was small. According to the ISO 17593:2007 standard, a sample size of 200 subjects and a correct selection of the sample distribution are required. The sample size limited the data performance and increased data variation.
The mean bias in the INR range of 2.0-4.5 was − 0.06 INR, which fulfilled the criterion of being within ± 0.3 INR. Table 1 shows that the mean and SD of the INR values between the two methods were extremely close to each other when the INR was below 4.5. When the INR was above 4.5, (3.1, 3.9) , and the outlier (1.4/2.1) were included in this group of nine. The other six cases might have occurred because of random variations in the two methods. The inconsistency from both random variation and from interference would result in approximately 10% of patients receiving the incorrect dosage. This result is superior to the values of 17.8% and 33% previously published using differing reference methods. [18, 19] The evidence suggests that values obtained from the CoaguChek XS Plus system should regularly be confirmed by the laboratory CA-1500 method. To avoid incorrect dosages being prescribed, we suggest that the tests be duplicated and the medication dosages be carefully monitored and adjusted.
Conclusions
This study evaluated the CoaguChek XS Plus system by comparing it with the laboratory CA-1500 method, using Thromborel S reagent. Although the small sample size limited our data reliability, most of the requirements of the ISO 17593:2007 standard were met. Our data showed that approximately 10% of patients would be prescribed the incorrect dosage, and we therefore suggest duplication of tests when monitoring INR values. Although the genetic factors VKORC1 and CYP2C9 or the clinical factors hypoalbuminemia and anemia did not reach the significant level, this study find that elevated AST and ALT level have effect on CoaguChek XS system analysis.
